Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.

An expert discusses how rilzabrutinib, a recently FDA-approved Bruton tyrosine kinase (BTK) inhibitor, targets the autoimmune ...

What Is Wayrilz, and Why Does It Matter? Wayrilz (rilzabrutinib) is a new oral medicine for adults with a long-lasting blood clotting disorder known as chronic immune thrombocytopenia (ITP) who ...